Innovent Biologics said Sunday it has signed an agreement with Eli Lilly to jointly develop novel therapies targeting cancer and immune system disorders, a move that could yield as much as $8.5 billion in milestone payments for the Chinese drugmaker.
Under the terms announced, Innovent and its subsidiaries will lead drug development from initial conception through Phase 2 clinical trials within China. Eli Lilly will obtain exclusive rights to further develop and commercialize any resulting treatments outside Greater China.
The deal includes a $350 million upfront payment to Innovent and the opportunity to receive additional milestone payments that could total roughly $8.5 billion. Innovent is also entitled to tiered royalties on sales of products that Eli Lilly ultimately brings to market.
This arrangement marks the seventh collaboration between the two companies. It differs from prior agreements in that it establishes joint development of new molecules rather than transferring rights to existing Innovent therapies to Eli Lilly.
Innovent described the collaboration as moving beyond traditional licensing relationships toward what it called an end-to-end innovation ecosystem. The company will carry responsibility for early-stage development activities in China, with Eli Lilly assuming responsibility for global development and commercialization outside that territory.
The structure of the deal separates geographic development and commercialization roles: Innovent handles conception and Phase 2 work within China, while Eli Lilly secures exclusive worldwide commercialization rights outside the Greater China region. Financial consideration for Innovent combines an initial cash payment, contingent milestone payments, and royalty streams tied to sales of any products marketed by Eli Lilly.
The announcement underscores a continued collaboration between the two firms, but also signals a change in how they will work together going forward, shifting from licensing finished assets to co-creating investigational therapies.